Tonabacase - iNtRON Biotechnology
Alternative Names: LSVT-1701; N-Rephasin® SAL200; SAL200Latest Information Update: 28 Feb 2025
At a glance
- Originator iNtRON biotechnology
- Developer iNtRON Biotechnology; Seoul National University Hospital
- Class Antibacterials; Coliphages; Endolysins; Endopeptidases; Proteins
- Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Feb 2025 Discontinued - Phase-II for Methicillin-resistant Staphylococcus aureus infections in South Korea (IV)
- 28 Feb 2025 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in South Korea (Intranasal)
- 28 Feb 2025 Discontinued - Preclinical for Vancomycin-resistant Staphylococcus aureus infections in South Korea (IV)